The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.
Rahul Jain, PhD
Advertisement
Articles by Rahul Jain, PhD
Advertisement
Latest Updated Articles
- Racial Variation in the Cost-effectiveness of Chemotherapy for Prostate Cancer
Published: May 18th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
2
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
3
Ibrutinib-Based Frontline Regimens Narrow the Survival Gap in CLL
4
New Proteomic Analysis Maps Cytokine Signatures Driving IPF
5
